Ten patients at Penn Medicine have been cured of the Hepatitis C virus (HCV) following lifesaving kidney transplants from deceased donors who were infected with the disease. The findings point to new strategies for increasing the supply of organs.
In 2016, Penn Medicine launched an innovative clinical trial to test the effect of transplanting kidneys from donors with HCV into patients currently on the kidney transplant wait list who do not have the virus, and who opt in to receive these otherwise unused organs. Recipients were then treated with an antiviral therapy in an effort to cure the virus.
Early data from the study were presented by David S. Goldberg, MD, MSCE, an assistant professor of Medicine and Epidemiology in the Perelman School of Medicine at the University of Pennsylvania, at the 2017 American Transplant Congress in Chicago, and were simultaneously published in the New England Journal of Medicine.
Journal article:http://www.nejm.org/doi/10.1056/NEJMc1705221
Source:https://www.sciencedaily.com/releases/2017/04/170430181150.htm
No comments:
Post a Comment